Two Sigma Investments LP Sells 62,728 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK)

Two Sigma Investments LP trimmed its holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 53.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 53,950 shares of the company's stock after selling 62,728 shares during the period. Two Sigma Investments LP owned 0.10% of Stoke Therapeutics worth $595,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also made changes to their positions in STOK. KLP Kapitalforvaltning AS acquired a new position in Stoke Therapeutics in the fourth quarter valued at about $63,000. Teacher Retirement System of Texas acquired a new position in shares of Stoke Therapeutics in the 4th quarter valued at approximately $113,000. Tower Research Capital LLC TRC lifted its holdings in shares of Stoke Therapeutics by 70.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 11,930 shares of the company's stock worth $132,000 after acquiring an additional 4,918 shares during the period. Invesco Ltd. acquired a new stake in shares of Stoke Therapeutics during the 4th quarter worth approximately $133,000. Finally, ProShare Advisors LLC acquired a new stake in shares of Stoke Therapeutics during the 4th quarter worth approximately $139,000.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on STOK shares. HC Wainwright cut their target price on Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating for the company in a research note on Wednesday, May 14th. Chardan Capital restated a "buy" rating and set a $24.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, March 19th. Needham & Company LLC reaffirmed a "buy" rating and issued a $22.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday, April 9th. Finally, Cantor Fitzgerald upgraded Stoke Therapeutics to a "strong-buy" rating in a research report on Wednesday, May 14th. Five analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, Stoke Therapeutics presently has an average rating of "Buy" and an average price target of $23.20.

Stoke Therapeutics Price Performance

Shares of NASDAQ STOK traded up $0.32 during mid-day trading on Thursday, hitting $11.82. 500,444 shares of the stock traded hands, compared to its average volume of 700,120. The company has a market cap of $645.34 million, a PE ratio of -5.63 and a beta of 1.09. Stoke Therapeutics, Inc. has a twelve month low of $5.35 and a twelve month high of $17.58. The firm has a 50 day simple moving average of $9.07 and a two-hundred day simple moving average of $9.66.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last posted its earnings results on Monday, March 24th. The company reported ($0.18) earnings per share for the quarter, topping analysts' consensus estimates of ($0.56) by $0.38. The firm had revenue of $22.61 million for the quarter, compared to analyst estimates of $4.20 million. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. On average, equities research analysts anticipate that Stoke Therapeutics, Inc. will post -2.01 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Barry Ticho sold 3,884 shares of the stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total transaction of $33,674.28. Following the completion of the sale, the insider now directly owns 63,962 shares in the company, valued at $554,550.54. This represents a 5.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Edward M. Md Kaye sold 10,382 shares of the business's stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total transaction of $90,011.94. Following the completion of the transaction, the director now owns 148,253 shares in the company, valued at approximately $1,285,353.51. The trade was a 6.54% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 24,748 shares of company stock valued at $225,687. Company insiders own 11.30% of the company's stock.

Stoke Therapeutics Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.